ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

NCT03003637 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Immunotherapy
Head and Neck Neoplasms

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

The Netherlands Cancer Institute